Pregabalin Capsule
Product Images NDC 71335-1751

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1751). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351751)

Pregabalin 50 mg oral capsule label by Bryant Ranch Prepack. The label shows the strength (50 mg), capsule form, and compares to Lyrica 50 mg capsules. Storage instructions note keeping at 20°-25°C and out of reach of children. The NDC 71335-1751 and a barcode are also visible.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Equation 1)

A mathematical formula for estimating creatinine clearance (CLCr) based on patient age, weight, serum creatinine levels, and adjustment for female patients. The formula involves multiplying the difference of 140 and age in years by weight in kilograms, adjusting by a factor of 0.85 for females, and dividing by 72 times serum creatinine in mg/dL.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph depicting the relationship between percent improvement in pain from baseline (x-axis) and percent of patients improved (y-axis). The graph compares multiple treatment groups, including Pregabalin 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and a placebo. Each treatment group is represented by a different line pattern, showing varying levels of patient improvement.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph depicting percent improved from baseline to week 12 based on BOCF, comparing the effects of Pregabalin versus placebo. The x-axis represents percent improvement, and the y-axis displays the percent of subjects improved, with two lines showing the difference between the two groups over the range of improvement percentages.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph showing the percent of subjects improved from baseline to Week 16 BOCF, comparing Pregabalin and placebo. The x-axis represents percent improvement, ranging from 0 to 100, and the y-axis represents the percent of subjects improved. The graph illustrates higher improvement rates for Pregabalin compared to placebo across various percent improvement levels.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph displaying the percent of patients improved versus percent improvement in pain from baseline. The graph compares two groups: one treated with Pregabalin 100 mg three times a day and a placebo group, showing differences in pain improvement over various thresholds.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line chart showing the percent of patients improved in pain over baseline versus percent improvement in pain from baseline. The chart compares Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day and a placebo. Different line styles represent each treatment group.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

Line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups over a range of pain improvement percentages.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph depicting percent improvement in pain from baseline on the x-axis against percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing the distribution of patient improvement percentages for each group.*

FDA Label Image

Epilepsy Study (Pregabalin Image 6)

A bar chart comparing responder rates (%) in two clinical studies labeled Study E1 and Study E3. The chart shows different pregabalin dosage groups versus placebo, displaying the proportion of responders for each group. Study E1 includes placebo, 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day groups. Study E3 shows placebo, 600 mg/day twice daily (BID), and 600 mg/day three times daily (TID) groups. Sample sizes (N) for each group are indicated below the bars.*

FDA Label Image

Studies E1, E2, And E3 (Pregabalin Image 7)

A line graph showing the median percentage change from baseline in seizure reduction versus dose (mg/day). The graph compares results from four studies labeled E1BD, E2 TID, E3 BD, and E3 TID, with markers distinguishing each study. Dose increases correspond to greater seizure reduction, with statistically significant p-values noted.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at daily doses of 600 mg, 450 mg, 300 mg, and a placebo. The graph shows separate lines for each dose group, illustrating comparative patient improvement percentages across varying pain improvement levels.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A Kaplan-Meier survival curve comparing the percentage of subjects without LTR between Pregabalin and Placebo groups over 180 days. The x-axis shows time in days, and the y-axis shows the estimated percentage of subjects without LTR. Pregabalin shows a higher percentage of subjects without LTR throughout the period compared to Placebo.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure of pregabalin, showing its molecular configuration with amino and carboxylic acid functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.